DexCom (DXCM) Tops Q2 EPS by 4c; updates guidance

DexCom (NASDAQ: DXCM) reported Q2 EPS of $0.43, $0.04 better than the analyst estimate of $0.39. Revenue for the quarter came in at $1 billion versus the consensus estimate of $1.04 billion.

GUIDANCE:

DexCom sees Q3 2024 revenue of $975-1000 million, versus the consensus of $1151 million.

DexCom sees FY2024 revenue of $4-4.05 billion, versus the consensus of $4.333 billion.

The company also announced a $750 million share repurchase program in conjunction with second quarter results.

For earnings history and earnings-related data on DexCom (DXCM) click here.

You May Also Be Interested In

• Deutsche Bank Starts DexCom (DXCM) at Buy
• Fusemachines wins AI demand planning deal with unnamed apparel brand
• Simulations Plus uses Nvidia BioNeMo toolkit for drug development AI